Metagenomi Therapeutics (MGX) Research & Development (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Research & Development of $19.3 million for Q1 2026, down 23.24% year-over-year from $25.1 million in Q1 2025, and down 10.24% quarter-over-quarter from $21.5 million in Q4 2025.
Metagenomi Therapeutics (MGX) Research & Development (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Research & Development for 4 consecutive years, with $19.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 23.24% year-over-year to $19.3 million; the TTM figure through Mar 2026 stood at $88.6 million (down 13.89% YoY), while the FY2025 annual figure was $94.4 million, down 13.51% from the prior year.
- Research & Development slipped to $19.3 million in Q1 2026 per MGX's latest filing, from $21.5 million in the prior quarter.
- Across five years, Research & Development topped out at $31.4 million in Q1 2024 and bottomed at $19.3 million in Q1 2026.
- Historically, Research & Development has averaged $24.4 million across 4 years, with a median of $24.8 million in 2023.
- Annual changes were most pronounced in 2024 — Research & Development soared 56.18% — and 2026, when it retreated 23.24%.
- Metagenomi Therapeutics' Research & Development stood at $24.8 million in 2023, then retreated by 6.43% to $23.2 million in 2024, then retreated by 7.18% to $21.5 million in 2025, then fell by 10.24% to $19.3 million in 2026.
- Business Quant data shows MGX's Research & Development at $19.3 million in Q1 2026, $21.5 million in Q4 2025, and $25.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Metagenomi Therapeutics | 45.38 Mn | 45.38 Mn | - | 22.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.51 Mn |
| Mar 31, 2026 | 19.30 Mn |
| Dec 31, 2025 | 21.50 Mn |
| Sep 30, 2025 | 25.28 Mn |
| Jun 30, 2025 | 22.51 Mn |
| Mar 31, 2025 | 25.14 Mn |
| Dec 31, 2024 | 23.16 Mn |
| Sep 30, 2024 | 26.26 Mn |
| Jun 30, 2024 | 28.32 Mn |
| Mar 31, 2024 | 31.44 Mn |
| Dec 31, 2023 | 24.76 Mn |
| Sep 30, 2023 | 26.84 Mn |
| Jun 30, 2023 | 22.68 Mn |
| Mar 31, 2023 | 20.13 Mn |